A sales partner offered a ray of hope that this company couldn't for itself.

Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.

CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting continued clinical progress, expanding uptake of Casgevy, and momentum across its ...

For most of his 20 years, a New Jersey man knew pain as a daily reality. Now, after a one-time CRISPR gene-editing treatment at Children's Hospital of Philadelphia, Austin Louis says he is finally ...

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia ...

CRISPR Therapeutics CRSP reported a fourth-quarter 2025 loss of $1.37 per share, wider than the Zacks Consensus Estimate of a loss of $1.15. The company had incurred a loss of 44 cents per share in ...

Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru crafted a bespoke treatment that has successfully corrected the genetic ...

Precedence Research, a leading strategic research firm, today released a comprehensive overview of the gene therapy and ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...

Gene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has been challenging. In the latest case, the scientists developed a CRISPR ...

When KJ Muldoon was born in August 2024 with mutations that led to a missing enzyme he needed to process proteins properly, Ahrens-Nicklas knew she had to act fast. Most with his condition need a ...

A research team has successfully demonstrated the world's first gene-editing treatment for Leber's hereditary optic ...